Practical Dermatology

???? ?? GIVING YOUR ALL FOR YOUR PATIENTS: Dermatologist Hilary Baldwin, M.D. talks with Practical Dermatology about her lectures at the 2024 Society of Dermatology Physician Associates (SDPA) annual meeting in Las Vegas covering acne and keloid management, as well as practical solutions for practitioners and some best practices for enhancing the quality of patient interactions. Watch the video ?? https://lnkd.in/e6qzmY3f #SDPA2024 #dermatology #acne #keloids #skin #professionaldevelopment

?? ?? ?? DUPILUMAB REVIEW: DUPIXENT? (dupilumab) HCP has emerged as a leading therapy for moderate-to-severe atopic dermatitis. In a new literature review of more than 60 real-world studies, data showed long-term survival rates of 80–90% over 3 years. Read the full story ? https://lnkd.in/gxq5NUDB #dermatology #atopicdermatitis #dupilumab #skin

? ?? ATOPIC DERM PEARLS: Dr. Matthew Zirwas discusses his passion for managing atopic dermatitis and shares key strategies for patient care at the Society of Dermatology Physician Associates (SDPA) annual conference in Las Vegas. Watch the video ?? ? https://lnkd.in/gjg8DD9s #SDPA2024 #SDPAconference #dermatology #atopicdermatitis #skin

?? ?? SUPPLEMENT STRATEGIES: Strategic supplement use can enhance dermatology care—but where to start? Sara M. Wilchowski, DMSc, PA-C, shared some of her insights with colleagues in her presentation, “Strategic Supplement Strategies for the Derm PA” from Society of Dermatology Physician Associates (SDPA)'s 22nd?Annual Fall Dermatology Conference in Las Vegas. Read the session coverage: ? https://lnkd.in/gNd7sTz9 #dermatology #PAinsights #supplements #SDPA

?? NEW APPROVAL: The FDA has approved BIMZELX? (bimekizumab-bkzx) HCP from UCB for adults with moderate-to-severe hidradenitis suppurativa (HS), making it the first treatment to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F). https://lnkd.in/e6tdnVch

?? THE LATEST IN EXOSOMES: Practical Dermatology talks with Todd Schlesinger, MD, a dermatologist and Mohs surgeon, and a member of the Editorial Board, about the latest updates in exosomes and what to expect next. This video was recorded at the Science of Skincare Summit in Austin. Watch the video ?? ? https://lnkd.in/eRce5xCH #exosomes #skincare #skin #dermatology

?? ?? ETHICAL RELATIONSHIPS WITH INDUSTRY: With collaboration central to progress, how can dermatology professionals maintain integrity in their partnerships with industry? Practical Dermatology Chief Medical Editor Neal Bhatia, MD, talks with Nada Elbuluk, MD, a dermatologist at the University of Southern California specializing in pigmentary disorders and skin of color, about building relationships with industry that maintain proper independence and compliance with professional ethics guidelines. This discussion was recorded at the Science of Skincare Summit in Austin. Watch here ?? ?? https://lnkd.in/e3GbWcrg #ScienceOfSkincareSummit #dermatology #ethics #skincare #skinhealth #professionalethics #industry

?????? SURGICAL INSIGHTS: A new study in the Journal of Drugs in Dermatology (JDD) suggests there is comparable effectiveness between Mohs surgery and wide excision for lentigo maligna melanoma treatment. ?? Read the full story ?? https://bit.ly/3AIxaQd #MohsSurgery #skincancer #melanoma #skin #dermatology #skin

???? ???? WHAT'S NEXT FOR EMROSI: At the Science of Skincare Summit in Austin, Practical Dermatology caught up with Chief Medical Editor Neal Bhatia, MD, and James Q. Del Rosso, DO, a dermatologist and Editor in Chief of Clinical Dermatology at the Journal of Clinical and Aesthetic Dermatology (JCAD), who shared insights and thoughts on the recent FDA approval of Emrosi (minocycline hydrochloride extended release capsules) for the treatment of rosacea. Watch the video?? ?? https://bit.ly/3CK6ezZ #skin #rosacea #dermatology #Emrosi #skincare #FDA

?? ???? TRuE-AD1 and TRuE-AD2: Ruxolitinib cream significantly reduces skin pain as early as 12 hours post-application and sustains improvements in symptoms and quality of life through 52 weeks, according to the results from two studies looking at ruxolitinib in individuals with mild-to-moderate atopic dermatitis. Read the story ?? https://bit.ly/40MJj17 #dermatology #atopicdermatitis #ruxolitinib #skinhealth #skin